Subsequently, three phase-III clinical trials demonstrated the benefit of pembrolizumab monotherapy in PD-L1 expressing previously treated advanced NSCLC in Keynote-010 [14] and treatment-naïve PD-L1 expressing advanced/metastatic NSCLC [4,15]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.